Premium
CHEMOIMMUNOTHERAPY IN DISSEMINATED MELANOMA AND COLORECTAL CARCINOMA
Author(s) -
GOUGH I.R.,
BOLTON P.M.,
CLUNIEAND G.J.A.,
BURNETT W.
Publication year - 1978
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1978.tb05233.x
Subject(s) - medicine , chemoimmunotherapy , colorectal cancer , melanoma , oncology , chemotherapy , immunotherapy , randomized controlled trial , intramuscular injection , fluorouracil , rectal carcinoma , surgery , gastroenterology , cancer , cancer research
Non‐specific immunotherapy with monthly intramuscular injection of Corynebacterlum parvum has been investigated by randomized clinical trials in patients with advanced cancer. Thirty‐six patients with disseminated melanoma were treated with either imidazole carboxamide (DTIC) alone or DTIC plus C. parvum. A 19% objective response rate was observed. The mean survival time was similar lor both groups. Thirty‐three patients with disseminated colorectal cancer were treated with either S‐fluorouracil (5FU) alone or 5FU plus C. parvum. No objective responses were observed. The mean survival time was similar for both groups. No advantage has been demonstrated in either tumour group by adding C. parvum to standard chemotherapy.